Can targeted drug cocktails erase hidden leukemia cells?
NCT ID NCT07131059
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing whether combining various chemotherapy and targeted drugs can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who are in remission but still have traces of leukemia cells. The study enrolls patients aged 14 and older with MRD-positive AML and evaluates different drug combinations to find the most effective and safe approach. The goal is to improve relapse-free survival by eliminating these hidden cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of chemotherapy and targeted drugs, including ivosidenib, gilteritinib, venetoclax, avapritinib, daunorubicin, cytarabine, idarubicin, mitoxantrone, homoharringtonine, azacitidine, ruxolitinib, and trametinib
- What this could lead to
- If successful, this could lead to more effective treatment strategies to eliminate residual leukemia cells and improve long-term remission and survival in AML patients.
- What could go wrong
- This is an early-stage platform trial, and the optimal drug combinations are still being explored. There is a risk of side effects, and not all patients may respond to the treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could early comfort care change End-of-Life for blood cancer patients?
- New cocktail targets tough leukemia mutations
- New Triple-Drug attack on aggressive leukemia shows promise in major trial
- Immune cells take on tough leukemia in early trial
- Blood transfusions guided by how you feel, not just lab numbers
- What matters most? new study puts quality of life first for older leukemia patients